Interventional cardiology

   

Product and therapy innovation

FlowMet peripheral blood flow monitoring system on a white background

Measurements that matter in the moment

The FlowMet? peripheral blood flow monitoring system provides continuous and objective measurements on the table, so you know your work is working.

VenaSeal closure system inside a white circle alongside an illustration of a blue leg

Reach new lengths with VenaSeal? closure system

Treat more diseased vein — maximize your impact. The VenaSeal closure system delivers immediate and lasting vein closure with its proprietary medical adhesive formula, with a demonstrated 94.6% closure rate at five years.1-5

Abre venous self-expanding stent system on a white background

Treating deep venous disease with a dedicated stent

The Abre? venous self-expanding stent system is designed for the unique challenges of venous disease. It offers easy deployment to let physicians focus on their patient, and delivers demonstrated endurance to give patients freedom of movement.6,7

Close-up illustration of the cusp overlap technique with TAVR within human anatomy shown under fluoroscopy

Cusp overlap technique with Evolut? TAVR

The cusp overlap technique brings precision and control to the TAVR procedure by isolating the noncoronary cusp, providing an accurate anatomical view to access and achieve the target implant depth. In combination with slow deployment starting at the supra-annular level, the valve is able to descend to its target position with minimal catheter manipulation, minimizing the risk of interaction with the conduction system.

Close-up illustration Endurant AAA stent graft sac regression within human anatomy

Addressing sac regression factors

Endurant? AAA stent graft demonstrates consistent and high sac regression rates across straightforward and complex anatomies.8,9 With:

  • Accurate placement and controlled deployment9
  • Continuous seal, fixation, and graft conformability9
  • Durable hemostatic barrier and resistance against type II endoleaks10
Close-up illustration of the Heli-FX EndoAnchor to reinforce the stent graft within the human anatomy

Call in the reinforcements

Endosuture aneurysm repair (ESAR) with the Heli-FX? EndoAnchor? system is your defense for patients at risk for suboptimal outcomes.

  • Reinforce the proximal seal11,12
  • Protect against neck dilatation13
  • Minimize type Ia endoleaks14
  • Promote greater sac regression15 

Evaluating the most complex high bleeding risk (HBR) patients on 1-month DAPT

Onyx ONE Clear Analysis evaluated Resolute Onyx? DES in complex patients, including those with acute coronary syndrome and diabetes, which led to several valuable subanalyses.16

Resolute Onyx stent on white background

Clinical evidence

12-month results from the ABRE clinical study

The ABRE clinical study demonstrates the safety and effectiveness of the Abre venous stent.6 Learn more about the study and the 12-month results.

Evolut TAVR hemodynamic data

The Evolut TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVR device to demonstrate hemodynamic superiority in a low-risk clinical trial versus SAVR at one year.19

Currently enrolling patients: SPYRAL HTN-ON MED trial?

Designed to determine the safety and efficacy of renal denervation (RDN) in the presence of up to three standard antihypertensive medications. Learn more at spyralhtntrials.com.

?Caution: Investigational device. Limited by federal (U.S.) law to investigational use.

Sustained effectiveness through 24 months for AV restenosis5

The IN.PACT? AV drug-coated balloon is the FIRST AND ONLY DCB to show superior and sustained results through two years in treating AV fistula lesions, compared to PTA.17,18

Onyx ONE Clear Analysis results now published

Read the Circulation: Cardiovascular Interventions article, evaluating Resolute Onyx DES in ~1,500 highly complex HBR patients on 1-month DAPT.

Currently enrolling patients: SPYRAL AFFIRM study

Designed to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral? RDN system in real-world patients with uncontrolled hypertension and associated comorbidities.

Education and training

Download the PCI eCatalog

View a comprehensive overview of all our educational offerings in percutaneous coronary intervention (PCI), from on-demand education to live programs.

Evolutions in TAVR patient care

Stay up to date on the latest evidence and key data releases in this series of short videos.

Addressing hypertension in the United States

This seven-part webinar series hosted by HTN clinical experts delves into several aspects of patient care, including diagnosis and treatment, establishing a care pathway, and addressing health equity.

Aortic virtual education

As your partner in the evolving healthcare landscape, we've developed various webinar series for real-time and on-demand learning with peer-to-peer discussion.

Medtronic Academy

Log in to Medtronic Academy to access a wide range of interactive courses, case studies, presentations, images, and videos from your phone, tablet, or desktop.

Visit Medtronic Academy

Connect with us????

Additional resources

References

1

Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. April 2015;61(4):985-994.

2

Proebstle T, Alm J, Dimitri S, et al. Three-year follow-up results of the prospective European Multicenter Cohort Study on Cyanoacrylate Embolization for treatment of refluxing great saphenous veins. J Vasc Surg Venous Lymphat Disord. March 2021;9(2):329-334.

3

Gibson K, Ferris B. Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: Initial outcomes of a post-market evaluation of the VenaSeal System (the WAVES Study). Vascular. April 2017;25(2):149-156.

4

Almeida JI, Javier JJ, Mackay EG, Bautista C, Cher DJ, Proebstle TM. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. September 2017;5(5):658-666.

5

Morrison N, Gibson K, Vasquez M, Weiss R, Jones A. Five-year extension study of patients from a randomized clinical trial (VeClose) comparing cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. J Vasc Surg Venous Lymphat Disord. November 2020;8(6):978-989.

6

ABRE CSR v1.2 30/JUL/2020.

7

Test data on file at Medtronic. Bench test results may not be indicative of clinical performance.

8

B?ckler D, Li C, Dansey K, et al. Sac regression is associated with lower all-cause mortality after contemporary endovascular aneurysm repair — a new paradigm for success. Presented online at ESVS 34th Annual Meeting, October 6, 2020.

9

Medtronic data on file.

10

Wakefield TW, Shulkin BL, Fellows EP, Petry NA, Spaulding SA, Stanley JC. Platelet reactivity in human aortic grafts: a prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits. J Vasc Surg. February 1989;9(2):234-243.

11

Melas N, Perdikides T, Saratzis A, Saratzis N, Kiskinis D, Deaton DH. Helical EndoStaples enhance endograft fixation in an experimental model using human cadaveric aortas. J Vasc Surg. June 2012;55(6):1726-1733.

12

Schl?sser FJV, de Vries JPPM, Chaudhuri A. Is it Time to Insert EndoAnchors into Routine EVAR? Eur J Vasc Endovasc Surg. April 2017;53(4):458-459.

13

Tassiopoulos AK, Monastiriotis S, Jordan WD, Muhs BE, Ouriel K, De Vries JP. Predictors of early aortic neck dilatation after endovascular aneurysm repair with EndoAnchors. J Vasc Surg. July 2017;66(1):45-52.

14

ANCHOR 4-year primary arm. 2019 data cut. Medtronic data on file.

15

Muhs BE, Jordan W, Ouriel K, Rajaee S, de Vries JP. Matched cohort comparison of endovascular abdominal aortic aneurysm repair with and without EndoAnchors. J Vasc Surg. June 2018;67(6):1699-1707.

16

Kandzari DE, Kirtane AJ, Windecker S, et al. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv. November 2020;13(11):e009565.

17

Holden A. Presented at Charing Cross 2021.

18

Trerotola SO, Saad TF, Roy-Chaudhury P. Lutonix AV Clinical Trial Investigators. The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis. J Vasc Interv Radiol. January 2020;31(1):1-14.e5.

19

Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.